People · Operator
Named in public records as an officer, director or promoter · active 2011–2013 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Asuragen Inc | — | Biotechnology | Series A | $12.5M | $271.1M | 2011 |
Ana J Ward at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ana J Ward on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Evan S. Melrose | 1 | 5 |
| Christopher D Earl | 1 | 3 |
| Matthew M Winkler | 1 | 2 |
| Lyle E. Arnold | 1 | 2 |
| Lynne J Hohlfeld | 1 | 1 |
| Carol J Berry | 1 | 1 |
| David J Sargent | 1 | 1 |
| David J Rubin | 1 | 1 |
| John E Mooney | 1 | 1 |
| Rolland M Carlson | 1 | 1 |
| Robert J Dominici | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.